AI-Powered Research

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 4 locations

Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations

Recruiting

Conditions: BRCA1/2
Genetic Testing

Interventions: Other: Salvia sample
Behavioral: Questionnaires

First Posted Date: 2018-01-10

Last Posted Date: 2025-02-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 350

Registration Number: NCT03396341

Locations: 🇺🇸
Dana Farber Cancer Institute (Data Collection Only), Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 4 locations

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Capecitabine
Drug: Neratinib
Behavioral: EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30

First Posted Date: 2017-12-19

Last Posted Date: 2025-04-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 34

Registration Number: NCT03377387

Locations: 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
🇺🇸
Baptist Alliance - McI, Miami, Florida, United States

and more 7 locations

Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening

Completed

Conditions: Breast Cancer
Breast Benign

Interventions: Device: Breast MRI
Device: Breast Mammogram
Other: Blood draw
Procedure: Breast Biopsy
Behavioral: online participant reported questionnaire

First Posted Date: 2017-12-14

Last Posted Date: 2025-03-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 628

Registration Number: NCT03372902

Locations: 🇺🇸
Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Baptist Alliance MCI, Miami, Florida, United States

and more 4 locations

Collecting Information About Treatment Results for Patients With Cushing's Syndrome

Recruiting

Conditions: Cushing's Disease
Cushing Syndrome
Cushing Disease

Interventions: Other: Cushing's QoL (Quality of Life Questionnaire)
Other: Nottingham Health Profile (NHP)
Other: Hospital Anxiety and Depression Scale (HADS)
Other: Perceived Stress Scale (PSS)
Other: Barratt's Impulsivity Scale (BIS)
Other: Beck Depression Inventory (BDI)
Other: State-Trait Anxiety Inventory (STAI)
Other: State Food Craving Questionnaire-State (FCQ-S)
Other: Trait Food Craving Questionnaire-Trait (FCQ-T)
Other: Visual Analogue Scale (VAS)
Other: Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant

First Posted Date: 2017-12-07

Last Posted Date: 2025-02-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 200

Registration Number: NCT03364803

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

and more 4 locations

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

Phase 1

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: rituximab
Drug: bendamustine
Drug: melphalan
Procedure: Autologous Stem Cell Transplantation (ASCT)

First Posted Date: 2017-11-24

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT03352765

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

BRCA Founder OutReach (BFOR) Study

Active, not recruiting

Conditions: BRCA1 Mutation
BRCA2 Mutation

Interventions: Other: BFOR Digital Health solution/Web Portal

First Posted Date: 2017-11-24

Last Posted Date: 2025-06-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 5412

Registration Number: NCT03351803

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

and more 2 locations

Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Behavioral: patient-reported pain scores
Drug: Bupivacaine
Other: saline

First Posted Date: 2017-11-22

Last Posted Date: 2024-12-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 144

Registration Number: NCT03351348

Locations: 🇺🇸
Memorial Sloan Kettering Commack (Consent and follow-up only), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau (Consent and follow-up only), Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (Consent and follow-up only), Harrison, New York, United States

and more 4 locations

Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity

Completed

Conditions: Central Nervous System Lymphoma

Interventions: Diagnostic Test: Resting State fMRI (rsfMRI)
Other: Auditory Attention and Executive Functions Test
Other: Memory Test
Other: Motor Speed Test
Other: Self Reported Quality of Life Questionnaire